title: Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation.
abstract: There are strong indications that only a small fraction of grafts successfully engraft in clinical islet transplantation. One explanation may be the instant blood-mediated inflammatory reaction (IBMIR) elicited by tissue factor, which is produced by the endocrine cells. In the present study, we show that islets intended for islet transplantation produce tissue factor in both the transmembrane and the alternatively spliced form and that the membrane-bound form is released as microparticles often associated with both insulin and glucagon granules. A low-molecular mass factor VIIa (FVIIa) inhibitor that indirectly blocks both forms of tissue factor was shown in vitro to be a promising drug to eliminate the IBMIR. Thrombin-antithrombin complex (TAT) and FVIIa-antithrombin complex (FVIIa-AT) were measured in nine patients who together received 20 infusions of isolated human islets. Both the TAT and FVIIa-AT complexes increased rapidly within 15-60 min after infusion. When the initial TAT and FVIIa-AT levels were plotted against the increase in C-peptide concentration after 7 days, patients with an initially strong IBMIR showed no significant increase in insulin synthesis after 7 days. In conclusion, tissue factor present in both the islets and the culture medium and elicits IBMIR, which affects the function of the transplanted islets.
authors.affiliation: The Rudbeck Laboratory, University Hospital, 751 85 Uppsala, Sweden. helena.johansson@klinimm.uu.se
authors.forename: Helena
authors.initials: H
authors.lastname: Johansson
authors.forename: Agneta
authors.initials: A
authors.lastname: Lukinius
authors.forename: Lisa
authors.initials: L
authors.lastname: Moberg
authors.forename: Torbjörn
authors.initials: T
authors.lastname: Lundgren
authors.forename: Christian
authors.initials: C
authors.lastname: Berne
authors.forename: Aksel
authors.initials: A
authors.lastname: Foss
authors.forename: Marie
authors.initials: M
authors.lastname: Felldin
authors.forename: Ragnar
authors.initials: R
authors.lastname: Källen
authors.forename: Kaija
authors.initials: K
authors.lastname: Salmela
authors.forename: Annika
authors.initials: A
authors.lastname: Tibell
authors.forename: Gunnar
authors.initials: G
authors.lastname: Tufveson
authors.forename: Kristina Nilsson
authors.initials: KN
authors.lastname: Ekdahl
authors.forename: Graciela
authors.initials: G
authors.lastname: Elgue
authors.forename: Olle
authors.initials: O
authors.lastname: Korsgren
authors.forename: Bo
authors.initials: B
authors.lastname: Nilsson
mesh_terms: D000328:Adult; D017398:Alternative Splicing / Q000502:physiology; D000990:Antithrombin III / Q000502:physiology; D015942:Factor VIIa / Q000037:antagonists & inhibitors / Q000502:physiology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007249:Inflammation / Q000503:physiopathology; D007515:Islets of Langerhans / Q000502:physiology* / Q000648:ultrastructure; D016381:Islets of Langerhans Transplantation; D008297:Male; D008875:Middle Aged; D010447:Peptide Hydrolases / Q000502:physiology; D013925:Thromboplastin / Q000502:physiology*; D013997:Time Factors
chemical_list: C046193:antithrombin III-protease complex; D000990:Antithrombin III; D013925:Thromboplastin; D010447:Peptide Hydrolases; D015942:Factor VIIa